Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial


Por: Leal, L, González, MDB, Castán, C, Meira, F, Dueñas, G, Pich, J, Hernández-Meneses, M, Rico, V, García-Pouton, N, Agüero, D, de Lazzari, E, Tomé, A, Herrera, S, Muñóz, J, Almuedo, A, Prieto-González, S, Castro, P, Marcos, MA, Tuset, M, Paredes, R, Carbonell, C, Dalmau, D, Martínez, JA, Soriano, A and García, F

Publicada: 5 feb 2026
Resumen:
In 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission (2.7; 95% CI, 1.11-6.62), lower risk of requiring mechanical ventilation (0.43; 95% CI, 0.20-0.93) and shorter hospitalization duration (p = 0.008). Mortality was similar between arms (p = 0.675). Twenty-eight patients receiving siltuximab required rescue therapy while only 5 receiving corticosteroids (p < 0.001). Furthermore, patients receiving corticosteroids had a 53% lower risk of confirmed bacterial or fungal invasive infections (RR 0.47; 95% CI, 0.23-0.95; p = 0.0096). Our results show that initial treatment with corticosteroids was more effective than siltuximab in preventing disease progression, reducing intensive care unit admission, mechanical ventilation, with shorter hospital stays, and fewer infection in COVID-19 pneumonia. Despite numerous challenges, these findings provide valuable insights into optimizing therapeutic strategies, supporting corticosteroids as a preferred treatment over siltuximab in this setting.

Filiaciones:
Leal, L:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

González, MDB:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Castán, C:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Meira, F:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Dueñas, G:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Pich, J:
 Hosp Clin Barcelona, Clin Trials Unit, Barcelona, Spain

Hernández-Meneses, M:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Rico, V:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

García-Pouton, N:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Agüero, D:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

de Lazzari, E:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Tomé, A:
 Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain

Herrera, S:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

Muñóz, J:
 Univ Barcelona, Fac Med, Barcelona, Spain

 Inst Global Hlth ISGlobal, Barcelona, Spain

 Hosp Clin Barcelona, Dept Int Hlth, Barcelona, Spain

Almuedo, A:
 Univ Barcelona, Fac Med, Barcelona, Spain

 Inst Global Hlth ISGlobal, Barcelona, Spain

 Hosp Clin Barcelona, Dept Int Hlth, Barcelona, Spain

Prieto-González, S:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

 Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain

 Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain

Castro, P:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

 Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain

Marcos, MA:
 Univ Barcelona, Fac Med, Barcelona, Spain

 Inst Global Hlth ISGlobal, Barcelona, Spain

 Hosp Clin Barcelona, Dept Microbiol, Barcelona, Spain

Tuset, M:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Pharm, Div Med, Barcelona, Spain

:
 Germans Trias & Pujol Univ Hosp, Dept Infect Dis Serv, Badalona, Spain

Carbonell, C:
 Univ Hosp Salamanca, Dept Internal Med, Salamanca, Spain

Dalmau, D:
 Mutua Terrassa Univ Hosp, Terrassa, Spain

Martínez, JA:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

Soriano, A:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

García, F:
 Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain
ISSN: 17528054





CTS-CLINICAL AND TRANSLATIONAL SCIENCE
Editorial
Wiley-Blackwell, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 19 Número: 2
Páginas:
WOS Id: 001682200300001
ID de PubMed: 41641848
imagen Green Submitted, gold

MÉTRICAS